Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 451 to 460 of 2450 total matches.
Comparison Table: Inhaled Corticosteroids for Treatment of COPD (online only)
The Medical Letter on Drugs and Therapeutics • Sep 07, 2020 (Issue 1606)
bid
2 inh bid
1 inh bid
1 inh bid
An ICS plus a LABA improves lung function and reduces ...
View the Comparison Table: Inhaled Corticosteroids for Treatment of COPD
Table: Correct Use of Inhalers for COPD (online only)
The Medical Letter on Drugs and Therapeutics • Sep 07, 2020 (Issue 1606)
a click is heard, the inhaler is ready
to use
The dose indicator should count down by 1
Exhale fully ...
View the Table: Correct Use of Inhalers for COPD
Cenobamate (Xcopri) for Focal Seizures
The Medical Letter on Drugs and Therapeutics • Aug 24, 2020 (Issue 1605)
be tried as monotherapy before
considering use of two drugs concurrently.1 Despite
the availability ...
The FDA has approved cenobamate (Xcopri – SK Life
Science) for oral treatment of partial-onset (focal)
seizures in adults.
Phexxi - A Nonhormonal Contraceptive Gel
The Medical Letter on Drugs and Therapeutics • Aug 24, 2020 (Issue 1605)
), but
was never marketed.1
Phexxi — A Nonhormonal
Contraceptive Gel
CHOICE OF CONTRACEPTIVES — Intrauterine ...
The FDA has approved Phexxi (Evofem), a
nonhormonal prescription-only vaginal gel containing
lactic acid, citric acid, and potassium bitartrate, for
prevention of pregnancy. The gel is intended for on-demand
contraception; it is not effective when used
after intercourse. It was previously approved for
use as a vaginal lubricant (Amphora), but was never
marketed.
Ozanimod (Zeposia) for Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Aug 24, 2020 (Issue 1605)
),
a sphingosine 1-phosphate (S1P) receptor modulator,
for treatment of adults with relapsing forms of multiple ...
The FDA has approved ozanimod (Zeposia – Celgene),
a sphingosine 1-phosphate (S1P) receptor modulator,
for treatment of adults with relapsing forms of multiple
sclerosis (MS), including clinically isolated syndrome
(initial neurological episode), relapsing-remitting
disease, and active secondary progressive MS
(SPMS). It is the third oral S1P receptor modulator to
be approved in the US for treatment of relapsing forms
of MS; siponimod (Mayzent) is also indicated for use
in adults, and fingolimod (Gilenya) is approved for use
in patients ≥10 years old.
IV Artesunate for Severe Malaria
The Medical Letter on Drugs and Therapeutics • Aug 10, 2020 (Issue 1604)
in children and adults. It has been available
from the CDC on a compassionate use basis since
2007.1 ...
Artesunate for injection (Amivas LLC), a semi-synthetic
artemisinin derivative, is now approved
by the FDA for initial (induction) treatment of severe
malaria in children and adults. It has been available
from the CDC on a compassionate use basis since
2007. Artemether/lumefantrine (Coartem), another
artemisinin-based drug, was approved earlier for oral
treatment of uncomplicated Plasmodium falciparum
malaria. IV artesunate is now the only FDA-approved
injectable antimalarial drug available in the US; IV
quinidine has been discontinued.
Drugs Past Their Expiration Date
The Medical Letter on Drugs and Therapeutics • Jul 27, 2020 (Issue 1603)
on the label. Since our last article on this
subject,1 more data have become available.
SAFETY ...
Healthcare providers are often asked if drugs can
be used past their expiration date. Because of legal
restrictions and liability concerns, manufacturers do
not sanction such use and usually do not comment
on the safety or effectiveness of their products beyond
the date on the label. Since our last article on this
subject, more data have become available.
Durysta - A Bimatoprost Implant for Glaucoma
The Medical Letter on Drugs and Therapeutics • Jul 27, 2020 (Issue 1603)
(Rhopressa)1 can be added
or substituted if IOP fails to reach the target range
with a PGA alone.2 Improper ...
The FDA has approved an intracameral implant
containing the prostaglandin analog bimatoprost
(Durysta – Allergan) for reduction of intraocular
pressure (IOP) in patients with open-angle glaucoma
or ocular hypertension. Bimatoprost is also
available in 0.01% (Lumigan) and 0.03% (generics)
ophthalmic solutions for the same indication and in
a 0.03% solution (Latisse, and generics) for eyelash
enhancement. Durysta is the first ocular implant to
become available in the US for treatment of glaucoma.
Lumateperone (Caplyta) for Schizophrenia
The Medical Letter on Drugs and Therapeutics • Jul 27, 2020 (Issue 1603)
,
blunted affect).1 Second-generation antipsychotic
drugs are generally used for initial treatment ...
The FDA has approved lumateperone (Caplyta —
Intracellular Therapies), an oral second-generation
antipsychotic, for once-daily treatment of schizophrenia
in adults. It is the 13th second-generation antipsychotic
drug to be approved by the FDA for this indication.
Golodirsen (Vyondys 53) for Duchenne Muscular Dystrophy
The Medical Letter on Drugs and Therapeutics • Jul 27, 2020 (Issue 1603)
corticosteroid
deflazacort (Emflaza) were approved earlier.1,2
THE DISORDER — DMD is a progressive, X-linked ...
Golodirsen (Vyondys 53 — Sarepta), an antisense
oligonucleotide, has received accelerated approval
from the FDA for treatment of Duchenne muscular
dystrophy (DMD) in the ~8% of patients who have
mutations of the dystrophin gene that are amenable
to exon 53 skipping. It is the first drug to be approved
for this indication and the third to be approved for
treatment of DMD; the antisense oligonucleotide
eteplirsen (Exondys 51) and the oral corticosteroid
deflazacort (Emflaza) were approved earlier.